论文部分内容阅读
目的 :探讨抑癌基因p16和p53在胰腺癌中的表达与临床病理的关系及其在胰腺癌发病机制中所起作用。方法 :应用免疫组织化学方法检测 50例胰腺癌p16和p53蛋白的表达水平。结果 :p16蛋白表达阳性率为 4 8% ,组织学Ⅰ级阳性率 (80 % )显著高于Ⅱ级 (50 % )和Ⅲ级 (2 5% ) ;临床Ⅰ期阳性率 (80 % )显著高于Ⅱ期 (38 9% )和Ⅲ +Ⅳ期 (2 9 4 % )。p53蛋白表达阳性率为 54% ,临床Ⅰ期阳性率(2 6 7% )却显著低于Ⅱ期 (6 1 1% )和Ⅲ +Ⅳ期 (70 6 % )。p16发生缺失同时伴有p53基因突变 ,即p16(- )p53(+)共 17例 ,占 34%。结论 :胰腺癌发生中存在p16抑制途径和p53抑制途径改变 ,p16和p53蛋白异常在胰腺癌发生进展中起着重要作用。
Objective: To investigate the relationship between the expression of tumor suppressor genes p16 and p53 in pancreatic cancer and clinicopathological features and their roles in the pathogenesis of pancreatic cancer. Methods: Immunohistochemistry was used to detect the expression of p16 and p53 in 50 cases of pancreatic cancer. Results: The positive rate of p16 protein was 48%. The positive rate of histological grade Ⅰ (80%) was significantly higher than that of grade Ⅱ (50%) and grade Ⅲ (25%). The positive rate of clinical stage Ⅰ (80%) was significantly Higher than those in stage Ⅱ (38 9%) and stage Ⅲ + Ⅳ (294%). The positive rate of p53 protein expression was 54%. The positive rate of clinical stage Ⅰ (26.7%) was significantly lower than that of stage Ⅱ (61.1%) and stage Ⅲ + Ⅳ (70.6%). P16 loss accompanied by p53 gene mutation, p16 (-) p53 (+) in 17 cases, accounting for 34%. Conclusion: There is p16 pathway and p53 pathway in pancreatic cancer. The abnormal expression of p16 and p53 plays an important role in the development of pancreatic cancer.